Farmas USA

Buenos dias,

Yo creo que con subir la vela de ayer no hace falta decir mas.

XBI

MDGL

Siendo realistas, si yo las hubiera pillado en $20, seguramente en $50 ya las habría largado... así que los $265 no los habría visto ni de cerca.

siendo realistas ... si yo las hubiera pillado en $20 ya estarian vendidas en $22 :))))))))))

MDGL

bueno framus y lo que nos divertimos ? jeje saludos

mira que soy el primero en reconocer que me gusta este vicio ... pero la verdad es que ultimamente no me divierto un carajo

edito: futuros +0,5% ... a la espera del jobs report .... 

ADXS

Prelim. Data from Ongoing Metastatic, Castration Resistant Prostate Cancer (mCRPC) Phase 1/2 KEYNOTE-046 Study, Conducted in Conjunction with Merck (MRK) Evaluating ADXS-PSA

Findings will be highlighted in a poster discussion at the 2018 American Society of Clinical Oncology (ASCO)  June 2, from 4:45 pm to 6:00

DXS-PSA was tested alone or in combination with KEYTRUDA in an advanced and heavily pretreated patient population who had progressed on androgen deprivation therapy. A total of 13 and 37 patients were evaluated on monotherapy and combination therapy, respectively. Overall, the safety profile was consistent with findings from prior clinical studies using the Lm platform. Treatment-related adverse events (TRAEs) were mostly mild or moderate constitutional symptoms such as fever, chills, rigors, hypotension, nausea and fatigue, consistent with immune activation and manageable with standard care. One patient in the monotherapy arm was discontinued from the study due to a grade 4 TRAE related to cytokine release, which resolved within 24 hours using medical management. There were no new toxicities observed with the combination therapy. In all treated patients, those who received the combination therapy experienced the longest overall survival (OS) at data cut-off, with the median not having been reached at 13 months of follow-up.

https://www.streetinsider.com/FDA/Advaxis+%28ADXS%29+Announced+Prelim.+Data+from+Ongoing+Metastatic%2C+Castration+Resistant+Prostate+Cancer+%28mCRPC%29+Phase+12+KEYNOTE-046+Study%2C+Conducted+in+Conjunction+with+Merck+%28MRK%29+Evaluating+ADXS-PSA/14261086.html?si_client=intbro

CELG

Presents At Bernstein Thirty-Fourth Annual Strategic Decisions Conference - Slideshow

https://seekingalpha.com/article/4178558-celgene-celg-presents-bernstein-thirty-fourth-annual-strategic-decisions-conference-slideshow

hiring of David V. Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO)

Mr. Elkins has more than 25 years of finance, strategy, operations, supply chain and business development experience in the United States, Europe and emerging markets. He joins Celgene from Johnson & Johnson (J&J), where he was Worldwide Vice President and CFO for Consumer Products, Medical Devices and Corporate Functions

https://www.streetinsider.com/Corporate+News/Celgene+%28CELG%29+Names+David+V.+Elkins+as+CFO+Effective+August+1/14258759.html?si_client=intbro

SGYP

Synergy Pharma: Is Management Really That Bad?

A prescription ramp starting in March and a strategic partnership by August are bullish catalysts for the stock.

https://seekingalpha.com/article/4178647-synergy-pharma-management-really-bad